Search Results

There are 105107 results for: content related to: Phase II multicenter open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study

  1. Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer

    Intervention Review

    The Cochrane Library

    Vincent T Janmaat, Ewout W Steyerberg, Ate van der Gaast, Ron HJ Mathijssen, Marco J Bruno, Maikel P Peppelenbosch, Ernst J Kuipers and Manon CW Spaander

    Published Online : 28 NOV 2017, DOI: 10.1002/14651858.CD004063.pub4

  2. Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel- and platinum-resistant recurrent ovarian or primary peritoneal cancer: A phase II pilot study

    Journal of Surgical Oncology

    Volume 72, Issue 3, November 1999, Pages: 162–169, Sharad A. Ghamande and M. Steven Piver

    Version of Record online : 15 NOV 1999, DOI: 10.1002/(SICI)1096-9098(199911)72:3<162::AID-JSO9>3.0.CO;2-0

  3. Extra-ovarian Primary Peritoneal Carcinomas

    Textbook of Uncommon Cancer, Third Edition

    Alberto E. Selman, Larry J. Copeland, Pages: 437–446, 2006

    Published Online : 11 JUL 2006, DOI: 10.1002/0470030542.ch39

  4. The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer

    International Journal of Gynecological Cancer

    Volume 18, Issue 5, September/October 2008, Pages: 879–890, M.J. PALAYEKAR and T.J. HERZOG

    Version of Record online : 5 DEC 2007, DOI: 10.1111/j.1525-1438.2007.01144.x

  5. Erosive osteoarthritis during treatment with bevacizumab and paclitaxel in a patient with recurrent papillary serous carcinoma of the ovary

    International Journal of Gynecological Cancer

    Volume 18, Issue 2, March/April 2008, Pages: 379–383, A. JAISHUEN, J.P. BERRIOS-RIVERA, N. SIRISABYA, H.G. ZHENG, Y. LI and J.J. KAVANAGH

    Version of Record online : 11 JUL 2007, DOI: 10.1111/j.1525-1438.2007.01023.x

  6. Third-line chemotherapy in platinum- and paclitaxel-resistant ovarian, fallopian tube, and primary peritoneal carcinoma patients

    International Journal of Gynecological Cancer

    Volume 14, Issue 5, September 2004, Pages: 804–814, S. Tangjitgamol, H. T. See, S. Manusirivithaya, C. F. Levenback, D. M. Gershenson and J. J. Kavanagh

    Version of Record online : 10 SEP 2004, DOI: 10.1111/j.1048-891X.2004.014512.x

  7. You have free access to this content
    A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days

    Cancer

    Volume 103, Issue 9, 1 May 2005, Pages: 1932–1938, Sen H. Zhuang, Manish Agrawal, Maureen Edgerly, Susan Bakke, Herb Kotz, Paul Thambi, Ann Rutt, Frank M. Balis, Susan Bates and Tito Fojo

    Version of Record online : 30 MAR 2005, DOI: 10.1002/cncr.20977

  8. Poster Session 1

    International Journal of Gynecological Cancer

    Volume 16, Issue s3, September/October 2006, Pages: 624–694,

    Version of Record online : 10 OCT 2006, DOI: 10.1111/j.1525-1438.2006.00738.x

  9. Extraovarian Primary Peritoneal Carcinomas

    Textbook of Uncommon Cancer

    Alberto E. Selman, Larry J. Copeland, Pages: 485–495, 2012

    Published Online : 20 SEP 2012, DOI: 10.1002/9781118464557.ch34

  10. You have free access to this content
    Chemotherapeutic and targeted biological agents for metastatic bladder cancer: A comprehensive review

    International Journal of Urology

    Volume 21, Issue 7, July 2014, Pages: 630–637, Terence T Sio, Jocelyn Ko, Vinay K Gudena, Nitin Verma and Uzair B Chaudhary

    Version of Record online : 23 JAN 2014, DOI: 10.1111/iju.12407

  11. Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression

    Medicinal Research Reviews

    Volume 32, Issue 6, November 2012, Pages: 1220–1262, Stefania Nobili, Ida Landini, Teresita Mazzei and Enrico Mini

    Version of Record online : 3 MAR 2011, DOI: 10.1002/med.20239

  12. Evaluation of In Vitro Drug Interactions with Karenitecin, a Novel, Highly Lipophilic Camptothecin Derivative in Phase II Clinical Development

    The Journal of Clinical Pharmacology

    Volume 43, Issue 9, September 2003, Pages: 1008–1014, Judith A. Smith, Robert A. Newman, Frederick H. Hausheer and Timothy Madden

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270003255921

  13. You have free access to this content
    Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma

    Cancer

    Volume 98, Issue 8, 15 October 2003, Pages: 1664–1669, David Scott Miller, John A. Blessing, Samuel S. Lentz and D. Scott McMeekin

    Version of Record online : 9 SEP 2003, DOI: 10.1002/cncr.11690

  14. You have free access to this content
    A feasibility study of low-dose, prolonged oral topotecan in patients with advanced ovarian, fallopian tube, or primary peritoneal serous cancer who have attained a complete clinical response following platinum-based chemotherapy

    International Journal of Gynecological Cancer

    Volume 18, Issue 1, January/February 2008, Pages: 51–58, A.H. COMANDER and S.A. CANNISTRA

    Version of Record online : 15 MAY 2007, DOI: 10.1111/j.1525-1438.2007.00978.x

  15. Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer

    International Journal of Gynecological Cancer

    Volume 17, Issue 2, March/April 2007, Pages: 350–358, M. FRIEDLANDER, M. BUCK, D. WYLD, M. FINDLAY, B. FITZHARRIS, P. DE SOUZA, T. DAVIES, G. KALIMI, S. ALLAN, D. PEREZ and P. HARNETT

    Version of Record online : 11 JAN 2007, DOI: 10.1111/j.1525-1438.2007.00795.x

  16. You have free access to this content
    Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer

    Cancer

    Volume 116, Issue 22, 15 November 2010, Pages: 5251–5260, Lisa M. Hess, Nan Rong, Patrick O. Monahan, Paridha Gupta, Champ Thomaskutty and Daniela Matei

    Version of Record online : 3 NOV 2010, DOI: 10.1002/cncr.25487

  17. Aggressive Non-Hodgkin's Lymphomas

    Standard Article

    Wiley Handbook of Current and Emerging Drug Therapies

    Published Online : 15 SEP 2006, DOI: 10.1002/9780470041000.cedt003

  18. You have free access to this content
    Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma

    Cancer

    Volume 101, Issue 9, 1 November 2004, Pages: 2034–2041, Hossein Borghaei, Michael Millenson, Russell Schilder, Mitchell Alden, Andre Rogatko, Hao Wang, Kristin Padavic-Shaller and Mitchell R. Smith

    Version of Record online : 28 SEP 2004, DOI: 10.1002/cncr.20616

  19. 4-Factor Model for Overnight Returns

    Wilmott

    Volume 2015, Issue 79, September 2015, Pages: 56–63, Zura Kakushadze

    Version of Record online : 21 SEP 2015, DOI: 10.1002/wilm.10448

  20. You have free access to this content
    Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials

    British Journal of Clinical Pharmacology

    Volume 78, Issue 6, December 2014, Pages: 1228–1237, Roberto Iacovelli, Filippo Pietrantonio, Antonella Palazzo, Claudia Maggi, Francesca Ricchini, Filippo de Braud and Maria Di Bartolomeo

    Version of Record online : 20 NOV 2014, DOI: 10.1111/bcp.12449